Aegerion Pharmaceuticals Inc (AEGR) financial statements (2020 and earlier)

Company profile

Business Address ONE MAIN STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 6537612682
Cash and cash equivalents 653766137
Short-term investments   6545
Receivables 14178 
Inventory, net of allowances, customer advances and progress billings 59102
Inventory 59102 
Prepaid expense and other current assets2
Other undisclosed current assets 3955 
Total current assets: 17640714184
Noncurrent Assets
Property, plant and equipment 5521
Intangible assets, net (including goodwill) 253 
Goodwill 10   
Intangible assets, net (excluding goodwill) 243   
Restricted cash and investments    0
Other noncurrent assets 150
Prepaid expense and other noncurrent assets0
Total noncurrent assets: 2581021
TOTAL ASSETS: 43441714285
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 62442918
Accounts payable 111045
Accrued liabilities 5127179
Employee-related liabilities  784
Debt  343
Other undisclosed current liabilities 25(7)(8)(4)
Total current liabilities: 87402517
Noncurrent Liabilities
Long-term debt and lease obligation 23014 
Long-term debt, excluding current maturities 23014 
Liabilities, other than long-term debt 20  
Deferred tax liabilities, net  0  
Other liabilities 2   
Other undisclosed noncurrent liabilities  21708
Total noncurrent liabilities: 23221748
Total liabilities: 3192572925
Stockholders' equity
Stockholders' equity attributable to parent 11616011360
Common stock 0000
Treasury stock, value (35)(35)  
Common stock, share subscribed but unissued, subscriptions receivable    (0)
Additional paid in capital 519491369253
Accumulated other comprehensive income (loss) 0(0)00
Accumulated deficit (369)(295)(256)(193)
Total stockholders' equity: 11616011360
TOTAL LIABILITIES AND EQUITY: 43441714285

Income statement (P&L) ($ in millions)

9/30/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
 24015849 
Cost of revenue
(Cost of Goods and Services Sold)
 (52)(16)(5) 
Gross profit: 18814243 
Operating expenses (233)(171)(106)(61)
Other undisclosed operating income  20 
Operating loss: (45)(27)(62)(61)
Nonoperating income (expense) 1(2)0(1)
Investment income, nonoperating  000
Other nonoperating income (expense) 1(2)(0)(1)
Interest and debt expense (28)(10)(1)(2)
Other undisclosed income from continuing operations before equity method investments, income taxes    1
Loss from continuing operations before income taxes: (72)(38)(63)(62)
Income tax expense (2)(1)(0) 
Net loss available to common stockholders, diluted: (73)(39)(63)(62)

Comprehensive Income ($ in millions)

9/30/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss: (73)(39)(63)(62)
Other comprehensive income    0
Comprehensive loss: (73)(39)(63)(62)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 0(0)0 
Comprehensive loss, net of tax, attributable to parent: (73)(40)(63)(62)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: